Not recruitingISRCTN65900535
Effectiveness of infliximab (tumor necrotising factor-alpha antagonist) in the treatment of late-onset depressive spectrum disorder in patients of 60 years and above
Research studyNetherlandsDepression
Understand this study
- Listed locations
- Netherlands
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Leiden University Medical Center (LUMC) (The Netherlands)
- Sponsor type
- Hospital / academic medical center
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- Netherlands
- Age range
- Not clearly listed
- Official registry ID
- ISRCTN65900535
- Official title
Show the full official title
Effectiveness of infliximab (tumor necrotising factor-alpha antagonist) in the treatment of late-onset depressive spectrum disorder in patients of 60 years and above
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Netherlands
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Leiden University Medical Center (LUMC) (The Netherlands), a hospital or academic medical center.
Is this study still recruiting?
The registry lists this study as not recruiting.
